Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (Biodrugs), the International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today released a new policy paper: “Developing a Regulatory Framework Supporting Biosimilar Competition: The Opportunity for Tailored Clinical Biosimilar Development”
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that the Cámara Industrial de Laboratorios Farmacéuticos Argentinos (CILFA) has been accepted and welcomed as a new IGBA Associate Member.
- IGBA Statement // Solidarity Call to Action: To realize equitable global access to COVID-19 health technologies through sharing of knowledge, intellectual property and data (29 May 2020)
- IGBA Pays Tribute to Bill Haddad (4 May 2020)
- ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR” - IGBA is Joining Forces on Global Collaboration to Overcome COVID-19 (24 April 2020)
- IGBA Contributes to Global Discussion on Tailored Clinical Biosimilar Development with New Peer-Reviewed Scientific Paper (10 April 2020)